Showing results (691-700 of 764) with videos related to

Sort By:
Pageof 77
European Journal of Cancer (Oxford, England : 1990)|November 11, 2018
Survival with nal-IRI (liposomal irinotecan) plus 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in per-protocol and non-per-protocol populations of NAPOLI-1: Expanded analysis of a global phase 3 trialLi-Tzong Chen, Jens T Siveke, Andrea Wang-Gillam, et al.
Teaching and Learning in Medicine|April 13, 2026
Contemporary Step 1 Predictive Methods Across 12 US MD-Granting Medical SchoolsChristian C Steciuch, James H Baños, Todd A Bates, et al.
Future Oncology (London, England)|July 29, 2025
ABC-12: exploring the microbiome in patients with advanced biliary tract cancer in a first-line study of durvalumab (MEDI4736) in combination with cisplatin/gemcitabineEleni Vrana, Hayley Timmins, Ashley Osborne, et al.
Lancet (London, England)|November 30, 2015
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trialAndrea Wang-Gillam, Chung-Pin Li, György Bodoky, et al.
Scientific Reports|April 23, 2020
Impulsivity is a heritable trait in rodents and associated with a novel quantitative trait locus on chromosome 1Bianca Jupp, Silvia Pitzoi, Enrico Petretto, et al.
Cardiovascular Research|December 5, 2025
KLHL24 mutation drives intermediate filament degradation, mitochondrial dysfunction and fibrosis in heart failure patientsVeronika Ramovs, H Sophia Chen, Athina Patra, et al.
The Lancet. Oncology|April 20, 2023
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 studyJianming Xu, Ken Kato, Eric Raymond, et al.
Eclinicalmedicine|June 8, 2023
NET-02: a randomised, non-comparative, phase II trial of nal-IRI/5-FU or docetaxel as second-line therapy in patients with progressive poorly differentiated extra-pulmonary neuroendocrine carcinomaMairéad G McNamara, Jayne Swain, Zoe Craig, et al.
Nature Genetics|April 30, 2008
Soluble epoxide hydrolase is a susceptibility factor for heart failure in a rat model of human diseaseJan Monti, Judith Fischer, Svetlana Paskas, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 8, 2024
Somatostatin Receptor Imaging with [18F]FET-βAG-TOCA PET/CT and [68Ga]Ga-DOTA-Peptide PET/CT in Patients with Neuroendocrine Tumors: A Prospective, Phase 2 Comparative StudySuraiya Dubash, Tara D Barwick, Kasia Kozlowski, et al.
Pageof 77